Venezuela Power of Attorney 2026: Notarization Chain and Scope of Authority

Updated: 2026-11-12 · GRZAN Regulatory Team · Verification date 2026-10-20

1. Key takeaways

A power of attorney (POA) is the instrument by which a manufacturer grants authority to its authorized representative in Venezuela. It must pass through three steps: notarization, legalization (apostille or consular legalization), and translation into Spanish.

GRZAN’s assessment: the way the authority clause is drafted determines whether later variations, renewals and responses to deficiency letters can be advanced by the representative alone. A narrow clause, limited for example to filing the initial registration application, forces the manufacturer to issue a new POA for every renewal and every variation, and each re-issuance walks the three-step chain again. A broad clause, covering the whole registration lifecycle and post-market matters, covers the entire product life with a single authorization.

The cost difference between the two approaches is not the notary fee. It is the calendar time consumed each time a chain is rebuilt, taken at the moment when the file is already waiting in front of a reviewer or a customs officer. Because the authority clause is drafted once and used for years, it is one of the few decisions in a registration project where a small amount of additional care produces a durable return across the whole portfolio.

2. Legal basis

Regulation or documentReference numberPublication dateProvision or key point
Ley de Medicamentos (Medicines Law)Gaceta Oficial N° 37.006August 3, 2000Article 18: registration obligation and publication in the Official Gazette
Circular N° DGSACS/0002/2025DGSACS/0002/2025October 28, 2025Procedure handled through the COMEX platform; the representative is the operating subject on the platform
Decreto N° 5.165Decreto N° 5.165September 30, 2025Handling authority for legal regimes 3, 8 and 12

Scope statement: the requirement for a POA in Venezuelan registration, and its three-step legalization chain, derive from industry comparison material and are marked as a practical estimate.

3. Expert insights

Insight one: the scope of authority should match the full product lifecycle, not the first application.

The first registration itself takes months in practical terms, with a practical estimate of 10 to 36 months, and during that period the certificate will need renewal and the product will change. Designing the authority clause around the lifecycle avoids repeated trips through the legalization chain. This is the most expensive optimization available and also the one with the largest return, because it converts a recurring administrative project into a single event that is executed once and then referenced for years.

The triggers for a renewal or a variation are predictable in advance: certificate expiry, a change of manufacturing site, a change of product name or model, a change in the label, and a change of representative. Each of them requires somebody to act before the authority, and each of them is a moment when a narrow POA turns a routine filing into a new legalization project. Writing the clause against that list, rather than against the wording of the first application form, is therefore a straightforward exercise once the list exists.

Insight two: the POA and the representation agreement are two different documents with two different functions.

The POA establishes that the representative has the right to act on the manufacturer’s behalf, which is its external effect. The representation agreement allocates rights and obligations between the parties, which is its internal effect. Neither substitutes for the other: with a POA but no agreement, the manufacturer has no contractual hold over the representative; with an agreement but no POA, the representative has no authority to operate in the SACS and COMEX environments, however well the commercial relationship is defined. The agreement is also where notification duties, response deadlines and the consequences of a missed deadline belong, because those are obligations between the parties rather than powers exercisable towards the authority.

Insight three: after the 2025 platform migration, the practical importance of the POA has increased.

Because procedures are now handled on the COMEX platform, the operating subject of the platform account, the applicant and the responsible party largely coincide, which makes the POA the only instrument that proves authority to operate. An unclear authority clause translates directly into an operation that cannot be completed on the platform, and the failure appears at the moment of filing rather than at the moment of drafting. Reconciling the account holder, the named representative and the authority clause therefore belongs in the go-live check, not in the legal review.

Insight four: the exit clause of a POA matters as much as the grant.

Because a change of registration holder requires the cooperation of the outgoing holder, as discussed in the thirty-second article of this series, the POA should provide for termination conditions, cooperation obligations after termination, and the handover of documents. A POA without an exit clause creates a substantive obstacle at the moment the manufacturer most needs flexibility, namely when it decides to change representatives. The clause costs one paragraph at drafting and can save a full re-registration at the worst possible moment.

One further point is frequently missed at notarization. The notary confirms the identity and capacity of the signatory, but the chain of corporate authority behind that signatory, such as a board resolution or a power of delegation, may need to be produced as well. Where the signatory’s authority rests on an internal delegation, the document set should include the supporting corporate records, translated and legalized in the same manner. A POA that is properly notarized but unsupported at this level can still be questioned when the authority behind the signature is examined.

4. Practical recommendations

  1. Draft the authority clause around the full lifecycle, expressly listing filing, receiving and responding to deficiency letters, paying fees, collecting the certificate, handling renewals, handling variations, obtaining import permits, and performing post-market reporting obligations.
  2. Sign the POA and the representation agreement together, with each document referring to the other, and include the representative’s notification duties and deadlines in the agreement.
  3. Include clear termination and exit provisions in the POA, covering termination events, the method of notice, and the obligation to hand over documents and data.
  4. Run the notarization, legalization and translation of the POA in parallel with the CFS chain, so that serial handling does not delay the overall filing date.

5. Verification checklist

  • □ The authority clause covers lifecycle matters, not only the initial application
  • □ The POA and the representation agreement were signed together and refer to each other
  • □ The POA contains termination, exit and document handover provisions
  • □ The three-step chain (notarization, legalization, translation) is complete and within validity
  • □ The representative’s operating authority in the COMEX platform account has been confirmed as matching the POA

Regulatory information verified as of October 29, 2026.

For a product-specific feasibility assessment of Venezuela market entry, GRZAN’s regulatory team supports manufacturers, importers and authorized representatives with registration dossiers, conformity documentation and submissions to the Venezuelan health authority. Contact info@grzanglobal.com to discuss your project.

Disclaimer

Prepared by GRZAN from publicly available regulation. It is provided for general information only and does not constitute legal advice. Legislation and official fees are subject to change by the competent authority.

About GRZAN

GRZAN (Global Regulatory Zone Access Navigator) — the global market-access navigator for medical devices and IVDs.

GRZAN is a specialist consultancy for medical device and IVD market access, providing end-to-end regulatory solutions across the product lifecycle and making international market entry simpler and faster.

Key figures. More than 25 wholly owned subsidiaries worldwide covering 50+ countries and regions; chosen by 100+ listed and leading Chinese device manufacturers, with 4,000+ successful cases; 12+ years in the sector and 200+ regulatory training sessions and seminars delivered.

What we do. Global market access: multi-country registration programmes, technical documentation, regulatory advice. Clinical evidence: clinical evaluation reports (CER), usability studies, overseas clinical investigations. Quality systems: ISO 13485, MDSAP, FDA QMSR and BGMP implementation and audit readiness. Authorised representative and licence-holder services across Southeast Asia, Latin America, the Middle East, Africa, Europe and North America.

Why GRZAN. A real operating entity, with the certificate held by the manufacturer: our direct overseas subsidiaries act as the compliant local holder, so the regulatory relationship stays clear and you keep control rather than being tied to a distributor. Direct access to the team: no time-zone gap, no language barrier, no cultural gap. Review points anticipated: we know what FDA 510(k), EU MDR, Southeast Asian, Latin American and Middle Eastern reviewers look for, which shortens timelines and reduces deficiency letters. Pathway planning: pre-decision analysis and risk assessment before you commit.

Every engagement rests on three commitments: efficiency through pre-submission review, certainty through a clear pathway, and stability through a licence-holder that stays in place.

Take your devices global with GRZAN

We work with manufacturers worldwide to open new markets with a clear regulatory pathway.

Contact us
WhatsApp
QR Code
WhatsApp QR Code
Scan to chat on WhatsApp
Phone
Call
Office Mon-Fri 9:00-18:00
0755-88659477
Mobile 24/7 Service
+86 15816864648
Email
Mail